Many patients will progress along the MS spectrum to SPMS.
This campaign aims to educate UK healthcare professionals (HCPs) on secondary progressive MS (SPMS) and provide tools and resources to help HCPs to:
Drive earlier identification of people with SPMS
Monitor for signs of progression, such as cognitive changes, as part of your routine practice
Effectively manage your patients with progressive MS to help improve their quality of life and minimise their burden of disease
Together we want to act on this vital opportunity to effectively manage patients and direct them to the right services.
*This is not representative of a real patient
An introduction to SPMS
SPMS is a stage of disease which follows an initial RRMS course1
SPMS is defined as progressive accumulated disability with or without occasional relapses, minor remissions, and plateaus2
Approximately 85–90% of patients have RRMS at the time of diagnosis3 and 1 in 2 people with RRMS will advance to SPMS within 20 years4
The heterogeneity of MS4,5
Adapted from Drendou CA, et al. Nat Rev Immunol. 2015;15(9):545-548 and Larochelle C, et al. Trends Neurosci. 2016;39(5):325-339.
Globally, SPMS is the second most common form of MS with a prevalence that varies geographically – up to 57.8/100,000 in the UK3
Despite the recent advances in the understanding of the disease, the diagnosis and treatment of SPMS continues to be challenging in routine clinical practice3,6
HCP, healthcare professional; IL, interleukin; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SDMT, symbol digit modalities test; SPMS, secondary progressive multiple sclerosis; TNF, tumour necrosis factor; UK, United Kingdom.
- National MS Society. Types of MS. Available at: https://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progr.... Accessed November 2021.
- Lublin FD, Reingold SC. Neurology. 1996;46(4):907–911.
- Inojasa H, et al. J Neurol. 2019;268(4):1210–1221.
- Khurana V, Medin J; Poster presented at: the 7th Joint ECTRIM-ACTRIMS Meeting, 25–28 October 2017, Paris, France.
- Drendou CA, et al. Nat Rev Immunol. 2015;15(9):545–548.
- Larochelle C, et al. Trends Neurosci. 2016;39(5):325‒339.
- Bokyo A, et al. Mult Scler Relat Disord. 2021;50:102778. Epub. doi 10.1016/j.msard.2021.102778.